Table 1.
Baseline patient characteristics (n = 30)
| Characteristic | Number (%) |
|---|---|
| Mean age, years (range) | 70 (46–85) |
| Sex, male | 16 (55%) |
| ECOG PS 0 | 26 (87%) |
| LDH levels | |
| ≤ULN | 19 (63%) |
| >ULN | 11 (37%) |
| M stage (AJCC-8) | |
| M1a | 6 (20%) |
| M1b | 6 (20%) |
| M1c | 18 (60%) |
| Number of lesion sites | |
| 1 | 6 (20%) |
| 2–3 | 17 (57%) |
| >3 | 7 (23%) |
| Liver metastases present | 10 (33%) |
| BRAF status | |
| Mutant | 11 (37%) |
| Wild type | 19 (63%) |
| PD-L1 | |
| <1% | 13 (43%) |
| >1% | 17 (57%) |
| Previous systemic therapy | |
| Ipilimumab | 3 (10%) |
| No | 27 (90%) |
AJCC-8, eighth edition of the American Joint Committee on Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; ULN, upper limit of normal.